Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Disorder Clear all
Terminated Not applicable Interventional Results available

Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine

NCT01942486
View directory record Official record
Conditions
Migraine Disorders, Photophobia
Interventions
Investigational Coating
Device
Lead sponsor
University of Utah
Other
Eligibility
7 Years to 18 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 3 Interventional

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

NCT00044577
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine, tenofovir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475
View directory record Official record
Conditions
Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Interventions
gp100 antigen, interleukin-2, MART-1 antigen, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 29, 2026, 6:05 AM EDT
Terminated Phase 4 Interventional

A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.

NCT03101501
View directory record Official record
Conditions
Presbyopia
Interventions
Mitomycin c, Raindrop Near Vision Inlay
Drug · Device
Lead sponsor
Key-Whitman Eye Center
Other
Eligibility
41 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Bloomington, Minnesota • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT05207865
View directory record Official record
Conditions
Migraine, Episodic Migraine, Phonophobia, Photophobia
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Hawthorne, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 29, 2026, 6:05 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

NCT05024695
View directory record Official record
Conditions
Glaucoma
Interventions
MINIject™ Implant
Device
Lead sponsor
iSTAR Medical
Industry
Eligibility
46 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
28
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04445519
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
18 Years to 84 Years
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Side Effects of Atropine (SEA) Study

NCT03593044
View directory record Official record
Conditions
Myopia
Interventions
0.01% concentration atropine drops
Drug
Lead sponsor
Jeffrey J. Walline, OD PhD
Other
Eligibility
21 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"

NCT01860534
View directory record Official record
Conditions
Light Sensitivity
Interventions
eye covers
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 29, 2026, 6:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients

NCT04700657
View directory record Official record
Conditions
Ocular GVHD
Interventions
corneal sensation test
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 6:05 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Retinal Perfusion OCT Study

NCT07174401
View directory record Official record
Conditions
Glaucoma
Interventions
Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months., Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.
Drug · Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed No phase listed Observational

Long Term Follow-Up of Diabetic Retinopathy

NCT00001395
View directory record Official record
Conditions
Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy, Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 2 Interventional

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
AU-011, Suprachoroidal Microinjector, PDT Laser
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Not listed Not applicable Interventional

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

NCT02921568
View directory record Official record
Conditions
Retinal Disease, Glaucoma
Interventions
P200TE, Spectral OCT/SLO
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 29, 2026, 6:05 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss

NCT06670989
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Fixation training
Behavioral
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 29, 2026, 6:05 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

NCT07218796
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retinal Fundus Camera Evaluation

NCT02293174
View directory record Official record
Conditions
Normal Healthy Subjects With no Known Ocular Diseases
Interventions
Topcon TRC-NW400, TRC-NW8, TRC-NW400, Canon-CR2, Zeiss Visucam PRO
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Oakland, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

NCT00763061
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Restasis
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Prophylactic Anecortave Acetate in Patients With a Retisert Implant

NCT00570479
View directory record Official record
Conditions
Uveitis, Posterior, Glaucoma
Interventions
anecortave acetate
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
10 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 29, 2026, 6:05 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

NCT05265546
View directory record Official record
Conditions
Perception Disorders
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 29, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Refractive Accuracy of "2WIN" and Portable Autorefractors

NCT04249505
View directory record Official record
Conditions
Refractive Error - Myopia Axial, Astigmatism, Accomodation, Visual Impairment, Hyperopia of Both Eyes
Interventions
"2WIN" Photoscreener, "Plusoptix A12", "Retinomax"
Device
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
6 Months to 95 Years
Enrollment
708 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 29, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism

NCT01496066
View directory record Official record
Conditions
Cataract
Interventions
LAL (Light Adjustable Lens) and Light Deliver Device (LDD), Monofocal control IOL
Device
Lead sponsor
Calhoun Vision, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
17
States / cities
Fayetteville, Arkansas • Los Angeles, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 29, 2026, 6:05 AM EDT